NASDAQ · KROS
Keros Therapeutics, Inc.
Healthcare · Biotechnology
$11.52▲ 1.41% ($0.16)at close
As of 4:00 PM ET
Market cap
$228.41M
P/E
N/M
EPS (TTM)
-$4.20
Next earnings
Nov 4, 2026
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.
Only 4 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Annual revenue history contains a gap; multi-year changes are annualized over their actual fiscal-year span. Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.
1 more note
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
Data notes
Only 4 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Annual revenue history contains a gap; multi-year changes are annualized over their actual fiscal-year span. Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
- 10-yr revenue CAGR
- 19.6%
- Ending operating margin
- 0.0%
- Discount rate
- 10.5%
USD · TTM ending Jun 30, 2026 · Price used $11.52 · Price Oct 5, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 26.25% over the last year. Revenue declined 93.55% over the trailing twelve months. Operating margin moved from 0.13% to -675.82%. Free cash flow declined 191.35% over the trailing twelve months.
What the market seems to be pricing
The market is reacting to weaker business momentum more than just compressing the valuation multiple. Even if the shares already screen cheap on P/S, investors are still discounting lower future earnings power.
What would invalidate this read
Operating margin stands at -675.82%. Revenue declined 93.55% — this read reverses if that trend stabilizes. Free cash flow fell 191.35% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Return analysis
Company profile
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
10
Buy
7
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 4, 2026
Q3 FY26 · EPS est -$0.96 · Revenue est $14.76M
View
Institutional Sentiment
Keros Therapeutics, Inc. · KROS
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.